GLP1 analog semaglutide administration to T2D patients for a year was associated with reduced cognitive impairment compared to sitagliptin, and both cognitive decline and dementia incidence were lower than in patients treated with glipizide. The gene discussed is GCG; the disease is type 2 diabetes mellitus.